BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 21, 2026
Home » MRGPRX2 antagonists

Articles Tagged with ''MRGPRX2 antagonists''

Inflammatory

Hangzhou Innogate and Innorace divulge MRGPRX2 antagonists

March 5, 2026
Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented new Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists designed for use in the treatment of atopic dermatitis, irritable bowel syndrome, metabolic syndrome, migraine, pain, neuropathic pain, rheumatoid arthritis and urticaria, among others.
Read More
Inflammatory

MRGPRX2 antagonists disclosed in Arcus Biosciences patent

Feb. 27, 2026
Arcus Biosciences Inc. has reported piperidylurea compounds acting as Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists.
Read More
Dermatologic

New MRGPRX2 antagonists disclosed in Keythera patent

Nov. 11, 2025
Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of urticaria, allergy, asthma, pruritus, arthritis, nasal polyps, dermatitis and irritable bowel syndrome, among others.
Read More
Immune

Samjin Pharmaceutical divulges new MRGPRX2 antagonists

Sep. 1, 2025
Samjin Pharmaceutical Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, inflammatory bowel disease, arthritis and migraine.
Read More
Inflammatory

Incyte describes new MRGPRX2 antagonists

Aug. 21, 2025
Incyte Corp. has identified Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of inflammatory disorders.
Read More
Dermatologic

New MRGPRX2 antagonists disclosed in Humanwell Healthcare patent

July 4, 2025
Humanwell Healthcare (Group) Co. Ltd. has divulged Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of pain, autoimmune disease and dermatological disorders.
Read More
Inflammatory

Incyte divulges new MRGPRX2 antagonists

March 18, 2025
Incyte Corp. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of inflammatory disorders.
Read More
Inflammatory

Sanofi discovers new MRGPRX2 antagonists

March 5, 2025
Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.
Read More
Dermatologic

Beijing Primegene Therapeutics divulges new MRGPRX2 antagonists

Feb. 3, 2025
Beijing Primegene Therapeutics Co. Ltd. has synthesized Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of urticaria and asthma.
Read More
Respiratory

New MRGPRX2 antagonists disclosed in Septurna patent

Nov. 26, 2024
Septerna Inc. has divulged compounds acting as mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of asthma, cancer, multiple sclerosis, obesity, osteoarthritis, psoriasis, rheumatoid arthritis and ulcerative colitis, among others.
Read More
Previous 1 2 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 20, 2026.
  • ALN-5288 lowers tau levels in preclinical models

    BioWorld Science
    Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
  • International currency symbols

    Capital remains selective in ‘barbell’ biotech market

    BioWorld
    Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
  • Elderly hands holding broken brain structure

    Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

    BioWorld Science
    Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
  • Neuropathy illustrated in legs and feet

    LIT-002 is strong candidate for autism and neuropathic pain

    BioWorld Science
    Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing